Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
2 hedge funds and large institutions have $371K invested in Merrimack Pharmaceuticals, Inc. in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MPWT
MassMutual Private Wealth & Trust
Windsor,
Connecticut
|
+$371K |
Top Sellers
MACK Hedge Fund Activity: Q4 2024 in Review
2 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2024, worth a combined $371K.
Fund positioning in MACK was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was MassMutual Private Wealth & Trust, opening a new position worth an estimated $371K.
- 2 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $371K of Merrimack Pharmaceuticals, Inc. stock for Q4 2024.
- 2 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2024 and 2 closed out, a net change of 0 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2024 was MassMutual Private Wealth & Trust, an estimated $371K added.
Based on aggregated 13F filings for Q4 2024.